A New Turning Point in the Biotech Revolution: Market Trends in AI-Based Drug Development and Personalized Medicine by 2026
Editor
AI-Integrated Biotech Surpasses the Commercialization Threshold
In early 2026, the global biotechnology industry is encountering an unprecedented inflection point. AI-based drug development technologies, which have been the focus of research and development over the past five years, are finally beginning to show substantial commercial outcomes, accelerating structural changes across the entire pharmaceutical industry. According to the latest report by McKinsey, the global market size for AI-based drug development is expected to reach $18.2 billion in 2026, representing a 47% increase from the previous year. Notably, the drug development period, which traditionally took 10-15 years, is being reduced to an average of 6-8 years with the use of AI platforms.
The backdrop of this transformation includes the rapid advancement of computing power and the explosive increase in biological data. By the end of 2025, the global collection of genomic data surpassed 150 million cases, a 15-fold increase compared to 2020. With the dramatic improvement in the accuracy of machine learning algorithms based on this big data, the success rate of drug candidates has risen from the traditional 5-10% to 25-30%. Roche, headquartered in Basel, Switzerland, announced that three of its cancer drug candidates developed through its AI platform have simultaneously entered Phase 2 clinical trials, reducing development costs by 40% compared to traditional methods.
The Korean biotech industry is also experiencing rapid growth in line with these global trends. Samsung Biologics, located in Incheon, reported a revenue of 1.2 trillion won in Q4 2025, marking a 35% growth compared to the same period last year. Particularly, after introducing an AI-based biopharmaceutical production optimization system, production efficiency improved by 22%, serving as a key factor in securing additional orders from global pharmaceutical companies. Celltrion, headquartered in Songdo, is also releasing new products 30% faster through its self-developed AI-based biosimilar development platform, with plans to launch three new biosimilar products in the first half of 2026.
Acceleration of Personalized Medicine Commercialization
The field of Precision Medicine is also witnessing groundbreaking advancements in 2026. With the cost of genetic analysis falling below $100, it has crossed the threshold of popularization, leading to explosive growth in the personalized medicine market. The global market size for personalized medicine is expected to reach $780 billion by 2026, with the Asia-Pacific region projected to account for 28% of the market share. The growth in the East Asian market, centered around Korea, Japan, and China, is particularly notable.
Johnson & Johnson, headquartered in New Jersey, USA, announced that its personalized treatment platform provided tailored therapies to 150,000 patients in 2025, a 180% increase from the previous year. Clinical results revealed a 45% improvement in treatment success rates in the cancer treatment sector compared to existing standard therapies. Notably, the incidence of side effects among patients receiving personalized treatments decreased by 60% compared to traditional therapies. These achievements are attributed to the significant enhancement in the precision of AI algorithms that comprehensively analyze patients’ genetic characteristics, lifestyle patterns, and medical history.
Novartis, based in Basel, Switzerland, has taken a step further by commercializing a digital treatment platform capable of real-time patient monitoring and therapy adjustment. This platform, integrated with wearable devices, monitors patients’ vital signs 24/7, allowing AI to analyze treatment efficacy in real-time and automatically adjust medication dosages or treatment schedules. Among 2,500 diabetes patients participating in the 2025 pilot program, 87% showed improved blood sugar levels, a 32% higher success rate compared to existing therapies. Novartis plans to officially launch this platform in the European and North American markets in the first half of 2026, expanding services to 500,000 patients annually.
In Korea, innovations in the field of personalized medicine are also becoming prominent. The AI-based cancer treatment prediction system jointly developed by Bundang Seoul National University Hospital and Samsung Seoul Hospital has begun offering a service that analyzes patients’ genetic profiles and tumor characteristics to recommend optimal cancer drug combinations. Among 450 lung cancer patients treated with this system over the past six months, 73% showed better outcomes than standard therapies. Particularly, 35% of terminal patients who did not respond to existing treatments showed tumor size reduction or disease progression inhibition, surprising medical professionals.
The investment environment in the biotech sector is also undergoing significant changes in 2026. Venture capital and private equity firms are significantly increasing investments in AI-integrated biotech startups, with global biotech investment reaching $68 billion in 2025, a 28% increase from the previous year. Investments in the Asian region surged by 45%, accounting for 23% of global investments. Korean biotech companies are also benefiting from this investment boom, with domestic biotech companies attracting a record-high investment of 4.2 trillion won in 2025.
Moderna, headquartered in Massachusetts, USA, is achieving remarkable results in the development of personalized cancer vaccines using mRNA technology. According to interim results from a Phase 3 clinical trial released at the end of 2025, the three-year survival rate for melanoma patients receiving personalized mRNA cancer vaccines reached 85%, significantly higher than the 67% for existing therapies. These vaccines are custom-made by analyzing unique antigens found in each patient’s tumor, with a manufacturing period of just six weeks. Moderna plans to commercialize this technology from the second half of 2026, expecting to provide treatment to 100,000 patients annually.
Competition among global pharmaceutical companies is also taking on a new dimension. The paradigm is shifting from competition centered on blockbuster drugs to one focused on platform technology and data capabilities. Pfizer, based in New York, USA, announced a $15 billion investment in AI and digital health technologies in 2025, accounting for 35% of its total R&D budget. Notably, Pfizer reported significant effects in its Alzheimer’s treatment under development through its AI platform, with cognitive function improvement 40% better than existing treatments.
Changes in the regulatory environment are also accelerating the development of the biotech industry. The U.S. FDA announced new approval guidelines for AI-based medical devices and therapies in 2025, expected to reduce approval procedures by an average of eight months. The European Medicines Agency (EMA) has also established a fast-track approval pathway for personalized therapies, with 15 personalized treatments already approved through this route. The Korean Ministry of Food and Drug Safety has also begun operating a separate review track for AI-based medical devices starting in 2026, reducing the approval period from 12 months to six months.
Market Outlook and Investment Opportunities
The future outlook for the biotech industry in 2026 is very bright. The global biotech market size is expected to reach $1.2 trillion by 2026, with the AI-integrated biotech sector projected to account for 25% of the market share. The growth in the Asia-Pacific region is particularly notable, with an expected annual growth rate of 32%. Korea is expected to form the third-largest market in this region, following China and Japan, with the domestic biotech market size estimated to reach 35 trillion won by 2026.
From an investment perspective, the profitability of the biotech sector is also significantly improving. Previously, high failure rates and long development periods made investment recovery challenging, but the introduction of AI technology has increased success rates and shortened development periods, greatly enhancing investment attractiveness. In 2025, the average return on companies listed in the biotech IPO market was 145%, significantly exceeding the overall tech sector average of 87%. Companies with AI-based drug development platforms showed an average return of over 200%, attracting significant interest from investors.
However, despite these positive prospects, several risk factors remain. First, regulatory uncertainty due to the black-box nature of AI algorithms persists. Second, legal issues related to privacy protection could hinder the spread of personalized therapies. Third, competition for talent between established pharmaceutical companies and emerging biotech firms could increase development costs. Fourth, excessive reliance on AI technology poses the risk of neglecting proven research methodologies.
Nevertheless, experts maintain an optimistic view of the long-term growth prospects of the biotech industry. According to the latest report by Goldman Sachs, the AI-integrated biotech sector is expected to grow at an annual rate of 28% over the next decade, significantly exceeding the overall healthcare sector growth rate of 12%. The personalized medicine market is projected to grow to $2.5 trillion by 2030, with the Asian market expected to account for 40%.
The Korean biotech industry is also at the center of these global trends. With the government’s K-Bio New Deal policy and active private investment, Korea is increasingly likely to establish itself as a global biotech hub. Particularly, with the biopharmaceutical production capabilities centered around Samsung Biologics and Celltrion, along with the emergence of innovative drug development platforms based on AI technology, Korea is in a favorable position to secure international competitiveness. 2026 is expected to be the inaugural year for the Korean biotech industry to make a significant leap in the global market, requiring continued attention from investors and industry stakeholders.
The information included in this analysis is for general informational purposes only and should not be interpreted as investment solicitation or advice. Please consult a professional before making investment decisions.
